Gliclazide offers specific pharmacological and clinical advantages within the sulfonylurea class, including lower hypoglycemia risk and potential cardiovascular safety, supporting its individualized use.
No takes yet. Share an insight, caveat, or question.
May support gliclazide preference among sulfonylureas; leaves open prospective RCTs to confirm outcomes.
Gábor Winkler (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: